Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Bio FY 2015 Revenues Up 31 Percent

NEW YORK (GenomeWeb) – Pressure Biosciences today reported a 31 percent increase in full-year 2015 revenues.

For the 12 months ended Dec. 31, the life sciences sample preparation technologies company recorded $1.8 million in total revenues, up from $1.4 million a year ago.

Products and services revenue was nearly flat at $1.4 million, the firm reported. Its instrument sales increased to $835,611 from $799,472. Consumables sales were down slightly from $167,380 to $146,408. Grant revenue jumped to $387,700, attributable to a Small Business Innovation Research Phase II grant from the National Institutes of Health awarded in February 2015.

The firm's net loss applicable to common shareholders widened to $7.4 million, or $.36 per share, compared to $6.3 million, or $.44 per share, in FY 2014. The loss per share was affected by a change in the number of shares outstanding, which increased following private placements in July and September.

Pressure Bio's R&D spending increased 16 percent to $1.1 million from $952,555 in 2014. The firm's SG&A spending increased 17 percent to $3.6 million from $3.1 million in 2014, driven by employee stock compensation.

The firm ended the quarter with $116,783 in cash and cash equivalents.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.